Secondary Logo

Journal Logo

Corrigendum

Corrigendum: Comparison of Efficacy and Safety between First and Second Generation Drug-eluting Stents in Patients with Stable Coronary Artery Disease: A Single-center Retrospective Study

Author Information
doi: 10.1097/CM9.0000000000001482
  • Open

In the article “Comparison of Efficacy and Safety between First and Second Generation Drug-eluting Stents in Patients with Stable Coronary Artery Disease: A Single-center Retrospective Study” which appeared in vol.130, issue 14, page 1655 of Chinese Medical Journal,[1] “G1–DES included sirolimus–eluting stents (Partner, Lepu Medical, China; Firebird, MicroPort Medical, China), paclitaxel–eluting stents (Taxus and Taxus Liberté, Boston Scientific, USA). G2–DES included zotarolimus–eluting stents (Endeavor and Endeavor Resolute, Medtronic Vascular, USA), everolimus–eluting stents (Xience V and Xience Prime, Abbott Vascular, USA; Promus and Promus Element, Boston Scientific, USA), and domestic sirolimus–eluting stents (Firebird2, MicroPort Medical, China).” should be corrected as “G1–DES included sirolimus–eluting stents (Partner, Lepu Medical, China; Firebird and Firebird2, MicroPort Medical, China), paclitaxel–eluting stents (Taxus and Taxus Liberté, Boston Scientific, USA). G2–DES included zotarolimus–eluting stents (Endeavor and Endeavor Resolute, Medtronic Vascular, USA), everolimus–eluting stents (Xience V and Xience Prime, Abbott Vascular, USA; Promus and Promus Element, Boston Scientific, USA).” The original results and conclusions are not affected.

Reference

1. Liu R, Xiong F, Wen Y, Ma YL, Yao Y, Gao Z, et al. Comparison of Efficacy and Safety between First and Second Generation Drug-eluting Stents in Patients with Stable Coronary Artery Disease: A Single-center Retrospective Study. Chin Med J 2017; 130:1654–1661. doi: 10.4103/0366-6999.209904.
Copyright © 2021 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.